Pictured: Richard Steingart
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 19, 2014

Cancer treatments, both traditional treatments and newer targeted therapies, can lead to short-term and long-term heart problems.

Pictured: Diane Reidy
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, February 19, 2014

Cycle for Survival, Memorial Sloan Kettering’s nationwide indoor team cycling event, helps support research into rare cancers. Three researchers discuss how these funds benefit their research.

Pictured: Robert J. Motzer
In the Clinic
By Maureen Salamon, BA, Freelance Writer  |  Thursday, August 22, 2013

An international study led by Memorial Sloan Kettering found that pazopanib (Votrient®) controls cancer as effectively as sunitinib (Sutent®) while improving patients’ quality of life.

Pictured: Scott Armstrong, Michael Kuehn, Haijhua Chu, Monica Cusan & Andrei Kritsov
Profile
By Esther Napolitano, BS, Science Writer/Editor  |  Friday, July 12, 2013

Scott Armstrong specializes in the treatment of leukemia in children. His research focuses on the disease in children and adults.

Charles Sawyers, Kenneth Offit, and Larry Norton
Honor
By Eva Kiesler, PhD, Science Writer/Editor  |  Wednesday, May 22, 2013

Charles Sawyers, Larry Norton, and Kenneth Offit are being honored with special awards at the annual meeting of the world’s leading professional organization for cancer physicians and researchers.

Pictured: Robert Motzer & Suzanne Gornell
Video
By Allyson Collins, MS, Science Writer/Editor  |  Wednesday, May 8, 2013

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

Pictured: Charles Sawyers
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, April 30, 2013

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Pictured: Gary Schwartz & Mark Dickson
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 22, 2013

Two clinical trials of targeted therapies led by Memorial Sloan Kettering investigators show promising results against different types of sarcoma.

Pictured: José Baselga
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 8, 2013

Memorial Sloan Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.

Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: Major Trends in Modern Cancer Research Seminar
Video
By Julie Grisham, MS, Science Writer/Editor  |  Friday, March 1, 2013

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Pictured: Charles Sawyers
Honor
By Media Staff  |  Wednesday, February 20, 2013

Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Pictured: Charles Sawyers' Laboratory
In the Clinic
By Media Staff  |  Monday, January 7, 2013

The American Society of Clinical Oncology’s notable research advances include the approval of a new drug for men with advanced prostate cancer that was developed and studied by Memorial Sloan Kettering researchers.

Pictured: PET Scan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 15, 2012

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Pictured: Ping Chi
Q&A
By Julie Grisham, MS, Science Writer/Editor  |  Friday, November 2, 2012

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.